News & Updates

The intermittent 48-h “gap” schedule of olaparib in combination with carboplatin/paclitaxel and anthracycline chemotherapy provides substantial survival benefits in patients with germline BRCA-mutated breast cancer (gBRCA) regardless of their pathological complete response (pCR) status, results of the PARTNER trial have shown.

Adding the PD-1/CTLA-4 bispecific antibody cadonilimab to chemotherapy improves overall survival (OS) and progression-free survival (PFS) in individuals with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer, including patients with PD-L1–low tumours, according to the interim results of the phase III COMPASSION-15 trial.

Adding immunotherapy to the first-line treatment for advanced and metastatic endometrial cancer may significantly improve some oncologic outcomes, particularly within the mismatch repair deficiency/microsatellite instability-hypermutated (MMRd/MSI-H) subset, suggests a study.

A large percentage of patients with relapsed/refractory multiple myeloma (RRMM) respond to the bispecific antibody linvoseltamab, with deep and durable responses seen even in the high-risk subgroups, according to data from the phase I/II LINKER-MM1 trial.

Several patients with metastatic castration-resistant prostate cancer (mCRPC) discontinue the use of androgen receptor‒targeted therapies (ARTs) because of disease progression, while a few stopped ARTs due to treatment toxicity, according to a study.